Under construction – not a live service
Sign in
Not yet taking people in United StatesPhase 1/2

Tests a smartphone memory training program in adults with schizophrenia or related illness

Tests a smartphone memory training program in adults with schizophrenia or related illness.

Plain-language title generated from the registry record
Registry title: A Cognitive Mobile Intervention for Motivation in Psychotic Disorders

Key facts

Where
Birmingham, United StatesSee the site
Phase
Phase 1/2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT07674914, who can take part

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Alabama at Birmingham
Trial code
NCT07674914
Record updated
30 June 2026
Original description
The goal of this study is to develop and test the impact of a smartphone-based working memory cognitive training digital therapeutic for individuals with schizophrenia or a related disorder.Read full original descriptionShow less

A User-Informed Digital Therapeutic for Specific Cognitive Disabilities to Improve Mental Health in Schizophrenia and Related Mental Illnesses

The goal of this study is to develop and test the impact of a smartphone-based working memory cognitive training digital therapeutic for individuals with schizophrenia or a related disorder.

Inclusion: diagnosis of schizophrenia, schizoaffective disorder, or a related psychotic disorder; own a smartphone; English speaking; experiencing challenges with cognitive functioning; no changes to antipsychotic medication in past month.

Exclusion: history of neurological disorder; traumatic brain injury with loss of consciousness > 10 minutes or behavioral sequelae.

ClinicalTrials.gov NCT07674914